Eugene P Rhee1,2, Eliseo Guallar3, Seungyoung Hwang3, Noori Kim4, Marcello Tonelli5, Sharon M Moe6, Jonathan Himmelfarb7, Ravi I Thadhani1, Neil R Powe8, Tariq Shafi9. 1. Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts. 2. Endocrinology Unit, Massachusetts General Hospital, Boston, Massachusetts. 3. Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Medicine, University of Calgary, Calgary, Alberta, Canada. 6. Division of Nephrology, Indiana University School of Medicine, Roudebush Veterans Administration Medical Center, Indianapolis, Indiana. 7. Kidney Research Institute, Division of Nephrology, University of Washington School of Medicine, Seattle, Washington. 8. Department of Medicine, Zuckerberg San Francisco General Hospital, San Francisco, California. 9. Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi.
Abstract
BACKGROUND: Uremic symptoms are major contributors to the poor quality of life among patients on dialysis, but whether their prevalence or intensity has changed over time is unknown. METHODS: We examined responses to validated questionnaires in two incident dialysis cohort studies, the Choices for Health Outcomes in Caring for ESRD (CHOICE) study (N=926, 1995-1998) and the Longitudinal United States/Canada Incident Dialysis (LUCID) study (N=428, 2011-2017). We determined the prevalence and severity of uremic symptoms-anorexia, nausea/vomiting, pruritus, sleepiness, difficulty concentrating, fatigue, and pain-in both cohorts. RESULTS: In CHOICE and LUCID, respectively, mean age of the participants was 58 and 60 years, 53% and 60% were male, and 28% and 32% were black. In both cohorts, 54% of the participants had diabetes. Median time from dialysis initiation to the symptoms questionnaires was 45 days for CHOICE and 77 days for LUCID. Uremic symptom prevalence in CHOICE did not change from baseline to 1-year follow-up and was similar across CHOICE and LUCID. Baseline symptom prevalence in CHOICE and LUCID was as follows: anorexia (44%, 44%, respectively), nausea/vomiting (36%, 43%), pruritus (72%, 63%), sleepiness (86%, 68%), difficulty concentrating (55%, 57%), fatigue (89%, 77%), and pain (82%, 79%). In both cohorts, >80% of patients had three or more symptoms and >50% had five or more symptoms. The correlation between individual symptoms was low (ρ<0.5 for all comparisons). In CHOICE, no clinical or laboratory parameter was strongly associated with multiple symptoms. CONCLUSIONS: The burden of uremic symptoms among patients on dialysis is substantial and has not changed in the past 15 years. Improving quality of life will require identification of the factors that underlie the pathogenesis of uremic symptoms and better ways of removing the toxins that are responsible.
BACKGROUND: Uremic symptoms are major contributors to the poor quality of life among patients on dialysis, but whether their prevalence or intensity has changed over time is unknown. METHODS: We examined responses to validated questionnaires in two incident dialysis cohort studies, the Choices for Health Outcomes in Caring for ESRD (CHOICE) study (N=926, 1995-1998) and the Longitudinal United States/Canada Incident Dialysis (LUCID) study (N=428, 2011-2017). We determined the prevalence and severity of uremic symptoms-anorexia, nausea/vomiting, pruritus, sleepiness, difficulty concentrating, fatigue, and pain-in both cohorts. RESULTS: In CHOICE and LUCID, respectively, mean age of the participants was 58 and 60 years, 53% and 60% were male, and 28% and 32% were black. In both cohorts, 54% of the participants had diabetes. Median time from dialysis initiation to the symptoms questionnaires was 45 days for CHOICE and 77 days for LUCID. Uremic symptom prevalence in CHOICE did not change from baseline to 1-year follow-up and was similar across CHOICE and LUCID. Baseline symptom prevalence in CHOICE and LUCID was as follows: anorexia (44%, 44%, respectively), nausea/vomiting (36%, 43%), pruritus (72%, 63%), sleepiness (86%, 68%), difficulty concentrating (55%, 57%), fatigue (89%, 77%), and pain (82%, 79%). In both cohorts, >80% of patients had three or more symptoms and >50% had five or more symptoms. The correlation between individual symptoms was low (ρ<0.5 for all comparisons). In CHOICE, no clinical or laboratory parameter was strongly associated with multiple symptoms. CONCLUSIONS: The burden of uremic symptoms among patients on dialysis is substantial and has not changed in the past 15 years. Improving quality of life will require identification of the factors that underlie the pathogenesis of uremic symptoms and better ways of removing the toxins that are responsible.
Authors: J Craig Longenecker; Michael J Klag; Santica M Marcovina; Yong-Mei Liu; Bernard G Jaar; Neil R Powe; Nancy E Fink; Andrew S Levey; Josef Coresh Journal: J Am Soc Nephrol Date: 2005-03-30 Impact factor: 10.121
Authors: A W Wu; N E Fink; K A Cagney; E B Bass; H R Rubin; K B Meyer; J H Sadler; N R Powe Journal: Am J Kidney Dis Date: 2001-01 Impact factor: 8.860
Authors: A Kalinska-Bienias; T Piotrowski; E Kowalczyk; A Lesniewska; M Kaminska; P Jagielski; C Kowalewski; K Wozniak Journal: Clin Exp Dermatol Date: 2019-01-16 Impact factor: 3.470
Authors: Albert W Wu; Nancy E Fink; Jane V R Marsh-Manzi; Klemens B Meyer; Frederic O Finkelstein; Michelle M Chapman; Neil R Powe Journal: J Am Soc Nephrol Date: 2004-03 Impact factor: 10.121
Authors: Steven D Weisbord; Sharon S Carmody; Frank J Bruns; Armando J Rotondi; Lewis M Cohen; Mark L Zeidel; Robert M Arnold Journal: Nephrol Dial Transplant Date: 2003-07 Impact factor: 5.992
Authors: Jiun-Ruey Hu; Leslie Myint; Andrew S Levey; Josef Coresh; Lesley A Inker; Morgan E Grams; Eliseo Guallar; Kasper D Hansen; Eugene P Rhee; Tariq Shafi Journal: Kidney Int Date: 2021-11-26 Impact factor: 10.612
Authors: Ziad A Massy; Nicholas C Chesnaye; Islam Amine Larabi; Friedo W Dekker; Marie Evans; Fergus J Caskey; Claudia Torino; Gaetana Porto; Maciej Szymczak; Christiane Drechsler; Christoph Wanner; Kitty J Jager; Jean Claude Alvarez Journal: Clin Kidney J Date: 2021-12-10
Authors: Keith McCullough; Friedrich K Port; Patricia de Sequera; Hugh Rayner; Roberto Pecoits-Filho; Sebastian Walpen; Pieter Evenepoel; Ronald L Pisoni Journal: Clin Kidney J Date: 2021-06-11
Authors: Meijiao Zhou; Linda H Ficociello; Claudy Mullon; Ann Mooney; Don Williamson; Michael S Anger Journal: ASAIO J Date: 2022-01-01 Impact factor: 2.872